[PE14] Poster Session 14
Clinical Immunology

[PE14-13] Oral once-daily berotralstat (BCX7353) reduces hereditary angioedema (HAE) events and is well-tolerated: pivotal phase 3 study (APeX-J) results from Japan

Isao Ohsawa¹, Daisuke Honda², Yusuke Suzuki³, Tomoo Fukuda⁴, Keisuke Koga⁵, Eishin Morita⁶, Shinichi Moriwaki⁷, Osamu Ishikawa⁸, Tomoe Kobayashi⁹, Yoshihiro Sasaki¹⁰, Masaki Tago¹¹, Greg Chittick¹², Sharon Murray¹², Sylvia Dobo¹², Eniko Nagy¹², Sharon Van Dyke¹², Lacy Reese¹², Phil Collis¹², William Sheridan¹², Michihiro Hide¹³ (1.Department of Nephrology, Saiyu Soka Hospital, Japan, 2.Juntendo University Urayasu Hospital, Japan, 3.Juntendo University Hospital, Japan, 4.Saitama Medical Center, Japan, 5.Community Hospital Koga Hospital, Japan, 6.Shimane University Hospital, Japan, 7.Osaka Medical College Hospital, Japan, 8.Gunma University Hospital, Japan, 9.Tomakomai City Hospital, Japan, 10.National Hospital Organization Disaster Medical Center, Japan, 11.Saga University Hospital, Japan, 12.BioCryst Pharmaceuticals, USA, 13.Hiroshima University, Japan)